Galvanize Therapeutics is a commercial-stage biomedical platform company operating at the convergence of engineering, biology and healthcare delivery.
Galvanize Therapeutics is developing therapies to deliver life-changing healthcare solutions to patients and their doctors at the convergence of biology, engineering, and care delivery.
Galvanize was created in from the merger with Gala Therapeutics and Galaxy Medical in 2022. The company was incubated by the life sciences venture capital firm ATP (Apple Tree Partners). Galvanize is headquartered in San Carlos, CA.
Galvanize Therapeutics has developed and refined a proprietary suite of Pulsed Electric Field (PEF) technologies built around the core Aliya platform. The Aliya PEF Energy platform utilizes short duration, high voltage, electrical pulses to create an electric field that destabilizes cells through multiple biochemical processes.
Galvanize's RheOx® system has CE Mark for treatment of chronic bronchitis symptoms, and its CENTAURITM system has CE Mark for treatment of paroxysmal atrial fibrillation.
Galvanize is backed by Fidelity Management and Research Company, ATP (Apple Tree Partners), Intuitive Surgical, Gilmartin Capital, and others. The company completed a $100M Series B round on Sep 15, 2022. This brings Galvanize's total funding to $148.5M to date.